Baird cuts target for UnitedHealth Group stock from USD 453 to USD 427

Published on 10/22/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter adjusted earnings hit USD 4.69 versus USD 4.14. UnitedHealth Group stock costs EUR 372.30 on October 22, 2026, 0.57 percent above Xetra close.

Operating trends and analyst caution

On October 14, 2026, Baird cut its UnitedHealth target from USD 453.00 to USD 427.00.
Third-quarter revenue reached USD 112.69 billion versus USD 111.40 billion expected.
UnitedHealth Group stock trades at EUR 372.30 at 10:49 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.57 percent above the Xetra close of October 21, 2026.

Bauhaus-Poster mit geometrischen Primärfarben, Schutzschild und stilisierten menschlichen Figuren — UnitedHealth Group US91324P1021 im Bauhaus-Stil mit geometrischen Formen Primärfarben und abstrakten Menschenfiguren, Illustration mit AI erstellt.

UnitedHealth Group (ISIN US91324P1021) was trading at EUR 372.30 at Lang & Schwarz on October 22, 2026 at 10:49 a.m. CEST, 0.57 percent above the Xetra close of October 21, 2026 at EUR 370.20. The key catalyst is a cautious analyst response after the insurer raised its full-year outlook.

On October 14, 2026, Baird analyst Michael Ha cut the price target from USD 453.00 to USD 427.00 while maintaining a Neutral rating, as Benzinga reported. Barclays analyst Andrew Mok also trimmed its target from USD 441.00 to USD 440.00 and retained an Overweight rating in the same October 14, 2026 report.

What does the target cut mean?

The target reductions point to valuation and execution risks rather than a weak third quarter. Raymond James later cut its target from USD 475.00 to USD 450.00, citing valuation, while the medical cost ratio improved to 88.4 percent from 89.9 percent a year earlier, according to Benzinga. For investors, the tension is clear: operating control is improving while analysts remain selective about valuation.

Three recent milestones

On July 16, 2026, UnitedHealth reported second-quarter revenue of USD 112.03 billion, based on the financial series for the period. On October 13, 2026, the company reported third-quarter revenue of USD 112.7 billion and earnings from operations of USD 6.6 billion, according to its UnitedHealth Group release. On October 14, 2026, Baird and Barclays revised their targets, with Baird making the larger cut.

The third-quarter report also showed adjusted earnings of USD 4.69 per share against USD 4.14 expected, while revenue exceeded the USD 111.40 billion estimate. UnitedHealth raised full-year 2026 adjusted earnings guidance to at least USD 20.50 per share from a previous range of USD 19.50 to USD 20.00. CNBC said the company was still managing elevated medical costs, despite the lower quarterly medical cost ratio.

Stock remains below its yearly high

UnitedHealth's primary listing is on the NYSE under ticker UNH. The primary-market quote was USD 417.00 at 4:00 p.m. ET on October 21, 2026, while the 52-week range stood at USD 255.97 to USD 461.62. The Lang & Schwarz euro indication is therefore the relevant German-market reference for this article.

UnitedHealth Group was trading at EUR 372.30 at Lang & Schwarz on October 22, 2026 at 10:49 a.m. CEST, 0.57 percent above the Xetra close of October 21, 2026 at EUR 370.20. The further course of trading is shown by the continuously updated real-time quote of UnitedHealth Group stock.